Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04955886 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

14

Enrollment

OTHER_GOV

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Surufatinib(HMPL-012)

Sponsor

Fujian Cancer Hospital